Date | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) |
---|
CEO | Dr. Tord Labuda M.Sc., Ph.D. |
IPO Date | Nov. 25, 2015 |
Location | Sweden |
Headquarters | Pepparedsleden 1 |
Employees | 5 |
Sector | Healthcare |
Industries |
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
Past 5 years
USD 20.24
USD 0.70
USD 0.16
USD 1.59
USD 0.11
StockViz Staff
February 6, 2025
Any question? Send us an email